Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus

Table 4 Adverse events, n (%)

Adverse events	Any grades			High grades (≥ 3)
	PTL (n = 18)	TL (n = 23)	P value	PTL (n = 18)	TL (n = 23)	P value
Asthenia	7 (38.9)	5 (21.7)	0.186	0 (0.0)	0 (0.0)	-
ALT elevation	14 (77.8)	18 (78.3)	0.665	2 (11.1)	3 (13.0)	0.851
AST elevation	13(72.2)	18 (78.3)	0.971	2 (11.1)	3 (13.0)	0.851
Hand-foot skin reaction	1 (5.6)	3 (13.0)	0.435	0 (0.0)	0 (0.0)	-
Hypertension	2 (11.1)	3 (13.0)	0.856	1 (5.6)	1 (4.3)	0.863
Hypothyroidism	2 (11.1)	0 (0.0)	0.163	0 (0.0)	0 (0.0)	-
Proteinuria	2 (11.1)	3 (13.0)	0.856	0 (0.0)	1 (4.3)	0.383
Dysphonia	0 (0.0)	1 (4.3)	0.383	0 (0.0)	0 (0.0)	-
Decreased WBC	5 (27.8)	4 (17.4)	0.438	1 (5.6)	0 (0.0)	0.264
Decreased PLT	6 (33.3)	4 (17.4)	0.249	0 (0.0)	1 (4.3)	0.383
Hypoproteinemia	4 (22.2)	3 (13.0)	0.451	0 (0.0)	0 (0.0)	-
Infection	1 (5.6)	1 (4.3)	0.863	0 (0.0)	1 (4.3)	0.383
Diarrhea	3 (16.7)	2 (8.7)	0.452	0 (0.0)	0 (0.0)	-
Hepatic encephalopathy	0 (0.0)	1 (4.3)	0.383	0 (0.0)	1 (4.3)	0.383
Myocarditis	1 (5.6)	0 (0.0)	0.264	1 (5.6)	0 (0.0)	0.264
Anorexia	3 (16.7)	4 (17.4)	0.953	0 (0.0)	0 (0.0)	-
Ascites	4 (22.2)	3 (13.0)	0.451	0 (0.0)	0 (0.0)	-
Acute kidney injury	1 (5.6)	1 (4.3)	0.863	1 (5.6)	1 (4.3)	0.863
Nausea	3 (16.7)	5 (21.7)	0.693	0 (0.0)	0 (0.0)	-
Decreased weight	2 (11.1)	4 (17.4)	0.584	0 (0.0)	0 (0.0)	-
Elevated bilirubin	1 (5.6)	1 (4.3)	0.863	1 (5.6)	0 (0.0)	0.264
Alimentary tract hemorrhage	0 (0.0)	1 (4.3)	0.383	0 (0.0)	1 (4.3)	0.383

PTL: PD-1 inhibitor/transcatheter arterial chemoembolization/Lenvatinib; TL: Transcatheter arterial chemoembolization/Lenvatinib; ALT: Alanine aminotransferase; AST: Aspartate transaminase; WBC: White blood cell; PLT: Platelet.